Compare · ADPT vs GILD
ADPT vs GILD
Side-by-side comparison of Adaptive Biotechnologies Corporation (ADPT) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADPT and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $165.39B, about 47.3x ADPT ($3.50B).
- Over the past year, ADPT is up 112.1% and GILD is up 23.0% - ADPT leads by 89.1 points.
- ADPT has been more active in the news (8 items in the past 4 weeks vs 4 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 16 for ADPT).
- Company
- Adaptive Biotechnologies Corporation
- Gilead Sciences Inc.
- Price
- $21.87-4.58%
- $133.19-0.77%
- Market cap
- $3.50B
- $165.39B
- 1M return
- +30.18%
- +6.15%
- 1Y return
- +112.12%
- +22.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 1992
- News (4w)
- 8
- 4
- Recent ratings
- 16
- 25
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ADPT
- Chief People Officer Lo Francis exercised 105,762 shares at a strike of $8.91 and sold $2,389,164 worth of shares (105,762 units at $22.59) as part of a pre-agreed trading plan (SEC Form 4)
- Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
- Chief Scientific Officer Robins Harlan S sold $8,501,149 worth of shares (386,240 units at $22.01) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 1,019,658 units (SEC Form 4)
- Chief People Officer Lo Francis exercised 75,621 shares at a strike of $8.75 and sold $2,157,683 worth of shares (95,842 units at $22.51) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 230,713 units (SEC Form 4)
- Chief Commercial Officer, MRD Bobulsky Susan sold $10,714 worth of shares (487 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 406,288 units (SEC Form 4)
- Chief Commercial Ofc Imm Med Benzeno Sharon exercised 114,329 shares at a strike of $7.75 and sold $3,503,510 worth of shares (165,802 units at $21.13) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 221,278 units (SEC Form 4)
- Chief Commercial Officer, MRD Bobulsky Susan sold $102,500 worth of shares (5,000 units at $20.50) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 406,775 units (SEC Form 4)
- Director Griffin Michelle Renee exercised 52,084 shares at a strike of $7.80 and sold $1,051,055 worth of shares (52,084 units at $20.18) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Adaptive Biotechnologies Corporation
- Adaptive Biotechnologies Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention